STOCK TITAN

Regeneron Pharmaceuticals - REGN STOCK NEWS

Welcome to our dedicated page for Regeneron Pharmaceuticals news (Ticker: REGN), a resource for investors and traders seeking the latest updates and insights on Regeneron Pharmaceuticals stock.

Overview

Regeneron Pharmaceuticals (NASDAQ: REGN) is a renowned American biotechnology company dedicated to inventing, developing, and commercializing transformative medicines for serious diseases. With its headquarters in Westchester County, New York, and a history dating back to 1988, Regeneron has established itself as a trusted innovator in the biopharmaceutical industry by consistently translating cutting‐edge science into life‐changing therapies.

Core Business and Technological Excellence

At the heart of Regeneron’s operations lies a deep commitment to scientific rigor and technological innovation. The company leverages proprietary VelociSuite® technologies, which include the groundbreaking VelocImmune® platform, to generate fully human antibodies and next-generation bispecific antibodies. These advanced techniques enable Regeneron to identify novel targets and rapidly develop therapies across a wide spectrum of indications such as eye diseases, immunologic disorders, oncology, cardiovascular diseases, neurologic conditions, hematologic disorders, and rare diseases.

Research, Development and Collaborative Approach

Regeneron’s robust R&D engine is fueled by decades of biology expertise and an integrated approach to drug discovery. The company’s research framework harnesses data-powered insights and genetic medicine platforms to drive its clinical research programs. This commitment is reflected in its diverse pipeline of product candidates and regulatory pathways that emphasize both innovation and patient safety. Through strategic partnerships and collaborations with other key industry players, Regeneron further strengthens its technological capacity while expanding its reach in translational medicine.

Market Position and Significance in the Biotechnology Sector

In the competitive landscape of biotech and pharmaceuticals, Regeneron distinguishes itself through its consistent ability to translate scientific discoveries into marketed products. Its portfolio comprises therapies addressing complex diseases by utilizing targeted approaches involving monoclonal antibodies and complementary biologic modalities. The company’s methodical process—from early identification of druggable targets to rigorous clinical testing and eventual commercialization—underscores its expertise, high scientific standards, and commitment to improving patient outcomes.

Operational Strategy and Business Model

Regeneron generates revenue primarily through its commercialization of innovative therapies and strategic collaborations, which amplify its research capabilities. By focusing on conditions with significant unmet medical need, Regeneron positions itself as a dynamic entity capable of addressing diverse therapeutic challenges. Its strategies incorporate efficient drug development processes, collaborative research initiatives, and maintaining robust clinical trial portfolios—all without relying on time-sensitive information or financial forecasts.

E-E-A-T Focus and Investor Considerations

The company’s work is grounded in long-standing scientific expertise and a commitment to ongoing research. By adhering to stringent safety and efficacy protocols and maintaining transparent regulatory communications, Regeneron exemplifies the principles of Expertise, Experience, Authoritativeness, and Trustworthiness (E-E-A-T). For investors and analysts, Regeneron’s approach to innovation, its state-of-the-art proprietary technologies, and its history of successfully translating advanced science into viable therapies present a well-articulated model of modern biotechnology excellence.

Conclusion

Overall, Regeneron Pharmaceuticals represents a compelling example of how rigorous research, technological innovation, and strategic partnerships converge to create transformative medicines. Its consistent emphasis on high-quality science and unbiased, evidence-based development processes not only boosts its market presence but also reinforces its reputation as a trusted biopharmaceutical partner in the global healthcare arena.

  • Decades of scientific expertise
  • Innovative proprietary platforms
  • Diverse therapeutic pipeline
  • Robust R&D and clinical programs
  • Strategic collaborations and transparency
Rhea-AI Summary

Regeneron Pharmaceuticals and Sanofi have announced positive Phase 3 trial results for Dupixent (dupilumab) in treating eosinophilic esophagitis (EoE) in children aged 1 to 11 years. The study, published in the New England Journal of Medicine, showed that a higher proportion of patients receiving weight-tiered higher dose Dupixent achieved significant improvements in EoE symptoms compared to placebo at week 16. These improvements were sustained for up to one year. The data supported the FDA's approval of Dupixent for this age group and are under review by the European Medicines Agency. The trial also found that Dupixent led to improvements in body weight for age percentile and had a safety profile consistent with its use in older patients.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.71%
Tags
-
Rhea-AI Summary

Regeneron Pharmaceuticals announced 14-month follow-up data from the LINKER-MM1 trial on linvoseltamab for relapsed/refractory multiple myeloma. The trial showed a 71% overall response rate (ORR) and 50% complete response (CR) or better. Median duration of response (DoR) was 29 months, and median overall survival (OS) was 31 months. Safety data were consistent with previous results, with cytokine release syndrome (CRS) in 46% of patients as the most common adverse event. Linvoseltamab showed better outcomes compared to real-world standard care. The U.S. FDA has given it Fast Track Designation and Priority Review, with a decision expected by August 22, 2024. The drug is also under review by the European Medicines Association and is in a Phase 3 confirmatory trial.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

Regeneron Pharmaceuticals and Sanofi announced FDA approval of Kevzara® (sarilumab) for treating active polyarticular juvenile idiopathic arthritis (pJIA) in patients weighing 63 kg or more.

This expands Kevzara’s use beyond adult chronic inflammatory conditions like rheumatoid arthritis and polymyalgia rheumatica. The approval is based on comprehensive studies and pharmacokinetic data from adults and pediatric patients.

Common adverse reactions include nasopharyngitis, neutropenia, and upper respiratory tract infection. KevzaraConnect® provides support services to help patients access the treatment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.88%
Tags
Rhea-AI Summary

Regeneron Pharmaceuticals and Sanofi announced that Dupixent (dupilumab) has been recommended for EU approval by the CHMP as an add-on maintenance treatment for adults with uncontrolled COPD marked by raised blood eosinophils. This recommendation is based on Phase 3 trials (BOREAS and NOTUS), where Dupixent showed a significant reduction in annualized moderate or severe acute COPD exacerbations by up to 34% compared to placebo and improved lung function and quality of life over 52 weeks. If approved, Dupixent would be the first targeted therapy for COPD in the EU and the first new treatment approach for COPD in over a decade. The European Commission's final decision is expected within months.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.06%
Tags
none
-
Rhea-AI Summary

Regeneron Pharmaceuticals and Sanofi announced that the U.S. FDA has extended the target action date for the priority review of Dupixent (dupilumab) by three months to September 27, 2024. This extension follows the submission of additional efficacy analyses requested by the FDA for the BOREAS and NOTUS pivotal trials. The FDA has no concerns about the approvability of Dupixent for treating uncontrolled COPD with type 2 inflammation. The companies are optimistic that this supplemental Biologics License Application (sBLA) will be approved. Additionally, reviews are ongoing with regulatory authorities in the EU and China. The EMA has already recommended approval in the EU. However, the safety and efficacy of Dupixent in COPD have not been fully evaluated by any regulatory authority.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.06%
Tags
-
Rhea-AI Summary

Biohaven has dosed its first patient in a Phase 1/2 study of BHV-1510, a Trop-2 directed antibody-drug conjugate (ADC) targeting advanced or metastatic epithelial tumors. BHV-1510 has shown promising preclinical results, including superior efficacy and a broader therapeutic margin compared to other Trop-2 ADCs. The study will evaluate the drug as a monotherapy and in combination with Regeneron's anti-PD-1 therapy, Libtayo®. Biohaven's proprietary ADC technology and partnership with Regeneron aim to advance treatment options in oncology, particularly for cancers with significant unmet medical needs.

The multicenter, open-label trial will have a dose-escalation phase followed by a multicohort expansion phase. Preclinical data suggests BHV-1510 could offer a better safety profile, including no lung toxicity, and improved clinical efficacy. The partnership with Regeneron will see Biohaven sponsor and fund the trial, while Regeneron supplies Libtayo. This initiative represents a key step in Biohaven's broader oncology strategy.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.69%
Tags
none
Rhea-AI Summary

Regeneron Pharmaceuticals announced promising results from a Phase 1/2 trial of their bispecific antibody REGN7075 combined with Libtayo in advanced solid tumors, particularly microsatellite stable colorectal cancer (MSS CRC). The trial showed a 6% overall response rate (ORR) and 29% disease control rate (DCR) among 51 MSS CRC patients. Positive results were noted, especially in patients without liver metastases. The combination therapy displayed an acceptable safety profile, with no dose-limiting toxicities or treatment-related deaths. Results will be presented at the ASCO 2024 Annual Meeting.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.45%
Tags
none
-
Rhea-AI Summary

Regeneron Pharmaceuticals and Sanofi have presented late-breaking data from the NOTUS Phase 3 trial, confirming positive results from the BOREAS trial. The data, presented at the 2024 American Thoracic Society International Conference and published in the New England Journal of Medicine, show Dupixent® (dupilumab) significantly reduced exacerbations by 34% and improved lung function in patients with uncontrolled chronic obstructive pulmonary disease (COPD) with type 2 inflammation. These results position Dupixent as a potential first-ever targeted therapy for COPD. Regulatory reviews are ongoing, with a U.S. FDA action date set for June 27, 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.51%
Tags
-
Rhea-AI Summary

Regeneron Pharmaceuticals and Society for Science awarded over $9 million to high school scientists at the 2024 Regeneron International Science and Engineering Fair (ISEF), the world's largest pre-college STEM competition.

Grace Sun won the top $75,000 award for her innovative organic electrochemical transistor. Michelle Wei and Krish Pai each received $50,000 for their respective projects in software efficiency and plastic biodegradation.

The competition, held in Tarrytown, NY and Washington, D.C., featured nearly 2,000 young scientists from 49 U.S. states and almost 70 countries. Other notable awards included $50,000 for a microplastics filtration system and $10,000 for a dementia multi-sensory therapy app.

Since 2020, Regeneron has provided STEM experiences to about 2.4 million students, aiming for 2.5 million by 2025. The fair emphasized the importance of fostering next-generation STEM leaders to tackle global challenges.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.48%
Tags
none
Rhea-AI Summary

Regeneron Pharmaceuticals, Inc. and Sanofi's sBLA for Dupixent® (dupilumab) in adolescents with Chronic Rhinosinusitis with Nasal Polyposis has been accepted for FDA Priority Review. If approved, Dupixent would be the first treatment in the U.S. for this condition in adolescents aged 12-17 years. The target action date for the FDA decision is September 15, 2024. The sBLA is based on positive pivotal trials in adults that showed Dupixent improved nasal congestion, polyp size, sense of smell, and reduced the need for systemic corticosteroids or surgery.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.32%
Tags

FAQ

What is the current stock price of Regeneron Pharmaceuticals (REGN)?

The current stock price of Regeneron Pharmaceuticals (REGN) is $617 as of April 1, 2025.

What is the market cap of Regeneron Pharmaceuticals (REGN)?

The market cap of Regeneron Pharmaceuticals (REGN) is approximately 67.6B.

What is the core focus of Regeneron Pharmaceuticals?

Regeneron is a biotechnology company that specializes in discovering, developing, and commercializing innovative medicines for serious diseases using advanced scientific and technological approaches.

Which technologies underpin Regeneron’s research efforts?

The company utilizes its proprietary VelociSuite® and VelocImmune® platforms, which are central to its ability to generate fully human antibodies and next-generation bispecific antibodies.

In which therapeutic areas does Regeneron operate?

Regeneron develops therapies across several areas including eye diseases, immunologic disorders, oncology, cardiovascular diseases, neurologic and hematologic conditions, as well as rare diseases.

How does Regeneron generate its revenue?

Revenue is primarily generated through the commercialization of approved therapies and strategic collaborations that enhance its research and development capabilities.

What differentiates Regeneron in the competitive biotech landscape?

Its commitment to cutting-edge technology, robust R&D pipeline, and a collaborative approach enable Regeneron to consistently transform scientific discoveries into marketable and efficacious treatments.

How long has Regeneron been active in the biotechnology field?

Regeneron was founded in 1988 and has since built a reputable track record for translating innovative science into transformative therapies.

What are the key elements of Regeneron’s business model?

The model emphasizes rigorous research and development, leveraging proprietary technologies, strategic partnerships, and a focus on addressing unmet medical needs while maintaining high standards of safety and efficacy.

How does Regeneron maintain its E-E-A-T (Expertise, Experience, Authoritativeness, Trustworthiness) standards?

By consistently investing in advanced research, adhering to strict clinical protocols, engaging transparently with regulatory authorities, and fostering innovations through collaborations, Regeneron demonstrates deep expertise and builds trust in the medical and investment communities.
Regeneron Pharmaceuticals

Nasdaq:REGN

REGN Rankings

REGN Stock Data

67.56B
105.70M
1.58%
91.4%
2.35%
Biotechnology
Pharmaceutical Preparations
Link
United States
TARRYTOWN